Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study

OBJECTIVE: PERFUSE is a non-interventional study of 1233 adult patients (rheumatology, n = 496; IBD, n = 737) receiving routine infliximab (IFX) biosimilar SB2 therapy. The aim of this report was to investigate the 12-month persistence, effectiveness and safety outcomes of routine SB2 treatment in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fautrel, Bruno, Bouhnik, Yoram, Dieude, Philippe, Richette, Pascal, Dougados, Maxime, Freudensprung, Ulrich, Brigui, Amira, Addison, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130189/
https://www.ncbi.nlm.nih.gov/pubmed/37122809
http://dx.doi.org/10.1093/rap/rkad031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130189/
https://www.ncbi.nlm.nih.gov/pubmed/37122809
http://dx.doi.org/10.1093/rap/rkad031

Ejemplares similares